A 4-year dopamine transporter (DAT) imaging study in neuroleptic-naive first episode schizophrenia patients |
| |
| Authors: | Anna Mané ,Judith GallegoFrancisco Lomeñ a,Jose Javier MateosEmilio Fernandez-Egea,Guillermo Horga,Albert Cot,Javier Pavia,Miguel Bernardo,Eduard Parellada |
| |
| Affiliation: | a Departament de Psiquiatria, Centre Fòrum Hospital del Mar, Barcelona, Spainb Departament de Biofísica, Universitat de Barcelona, Barcelona, Spainc Medicina Nuclear, Institut de Diagnòstic per la Imatge, Hospital Clínic, Barcelona, Spaind Institut d''Investigacions Biomèdiques Augusti Pi i Sunyer (IDIBAPS), Barcelona, Spaine Programa Esquizofrenia Clinic, Departament de Psiquiatria, Institut de Neurociencies, Hospital Clínic, Barcelona, Spainf Centre de Diagnòstic per la Imatge, Barcelona, Spaing Department of Psychiatry, University of Cambridge, Cambridge, United Kingdomh Cambridge and Peterborough NHS Foundation Trust, Cambridge, United Kingdomi Brain Imaging Laboratory, Division of Child and Adolescent Psychiatry, Columbia University, New York, NY, USAj Centro de Investigación Nacional en Red en Bioingeniería, Biomateriales y Nanomedicina, CIBER-BBN, Barcelona, Spaink Hospital Clínic de Barcelona, Institut de Neurociències, Barcelona, Spainl Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM, Barcelona, Spain |
| |
| Abstract: | Alterations in the dopaminergic system have long been implicated in schizophrenia. A key component in dopaminergic neurotransmission is the striatal dopamine transporter (DAT). To date, there have been no longitudinal studies evaluating the course of DAT in schizophrenia. A 4-year follow-up study was therefore conducted in which single photon emission computed tomography was used to measure DAT binding in 14 patients and 7 controls. We compared the difference over time in [123I] FP-CIT striatal/occipital uptake ratios (SOUR) between patients and controls and the relationship between this difference and both symptomatology and functional outcome at follow-up. We also calculated the relationship between baseline SOUR, symptoms and functional outcome at follow-up. There were no statistically significant differences between patients' SOUR changes over time and those of controls. A significant negative correlation was observed between patients' SOUR changes over time and negative symptomatology at follow-up. A significant negative correlation was also found between baseline SOUR in patients and negative symptomatology, and there was a significant association between lower SOUR at baseline and poor outcome. Although the study found no overall differences in DAT binding during follow-up between schizophrenia patients and controls, it demonstrated that differences in DAT binding relate to patients' characteristics at follow-up. |
| |
| Keywords: | Basal ganglia Outcome Negative Longitudinal |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
